

Barbara J Mintzes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545277/publications.pdf>

Version: 2024-02-01

122
papers

3,618
citations

201674

27
h-index

155660

55
g-index

126
all docs

126
docs citations

126
times ranked

3999
citing authors

#	ARTICLE	IF	CITATIONS
1	Industry effects on evidence: a case study of long-acting injectable antipsychotics. Accountability in Research, 2024, 31, 2-13.	2.4	0
2	Association Between Conflicts of Interest and Authors'™ Positions on Harms of Varenicline: a Cross-Sectional Analysis. Journal of General Internal Medicine, 2022, 37, 290-297.	2.6	3
3	Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. British Journal of Clinical Pharmacology, 2022, 88, 713-722.	2.4	8
4	Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. British Journal of Cancer, 2022, 126, 144-161.	6.4	5
5	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	3.7	6
6	Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO Oncology Practice, 2022, 18, e1154-e1163.	2.9	3
7	Australian Clinical Trial Authors'™ Declarations of Industry Ties. Journal of General Internal Medicine, 2022, 37, 3196-3198.	2.6	3
8	Industry Sponsor Influence in Clinical Trial Reporting in Canada: A Qualitative Interview Study. Clinical Therapeutics, 2022, 44, 374-388.	2.5	7
9	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	3.2	2
10	Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. International Journal of Drug Policy, 2022, 105, 103749.	3.3	4
11	Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. Pharmacoepidemiology and Drug Safety, 2022, 31, 1039-1045.	1.9	1
12	Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures. Internal Medicine Journal, 2021, 51, 1816-1824.	0.8	8
13	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology and Therapeutics, 2021, 109, 1424-1442.	4.7	12
14	Reply to Kelly Farrah and David Kaunelis regarding our study "Validation of five search filters for retrieval of clinical practice guidelines produced low precision". Journal of Clinical Epidemiology, 2021, 133, 156-157.	5.0	0
15	"There are ways" drug companies will get into DTC decisions: How Australian drug and therapeutics committees address pharmaceutical industry influence. British Journal of Clinical Pharmacology, 2021, 87, 2341-2353.	2.4	5
16	Editorial: Policing the promotion of prescription medicines - the new Medicines Australia Code of Conduct. Australian Prescriber, 2021, 44, 4-6.	1.0	2
17	"Lines in the sand"™: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. BMJ Open, 2021, 11, e045140.	1.9	6
18	Over half of clinical practice guidelines use non-systematic methods to inform recommendations: A methods study. PLoS ONE, 2021, 16, e0250356.	2.5	40

#	ARTICLE	IF	CITATIONS
19	A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). <i>Journal of General Internal Medicine</i> , 2021, 36, 3179-3187.	2.6	575
20	“Drugs to avoid” to improve quality use of medicines: how is Australia faring?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 60.	2.4	3
21	Long-acting antipsychotics: is what we know really so?. <i>Lancet Psychiatry</i> , 2021, 8, 651.	7.4	3
22	Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 185-188.	0.3	6
23	A sorry tale of unnecessary secrecy about medicine safety. <i>Internal Medicine Journal</i> , 2021, 51, 1765-1766.	0.8	0
24	“Drugs to avoid”: can we improve prescribing appropriateness?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 162-162.	0.3	0
25	Validation of five search filters for retrieval of clinical practice guidelines produced low precision. <i>Journal of Clinical Epidemiology</i> , 2020, 117, 109-116.	5.0	13
26	Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00680.	2.4	2
27	A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States – 2007 to 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1054-1063.	1.9	9
28	Communicating emerging risks of SGLT2 inhibitors – timeliness and transparency of medicine regulators. <i>BMJ, The</i> , 2020, 369, m1107.	6.0	7
29	US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS). <i>Pharmaceutical Medicine</i> , 2020, 34, 135-140.	1.9	9
30	A Cohort Study of Psychotropic Prescription Drug Use in Pregnancy in British Columbia, Canada from 1997 to 2010. <i>Journal of Women's Health</i> , 2020, 29, 1339-1349.	3.3	3
31	Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1416-1429.	2.4	6
32	UK deal over inclisiran. <i>BMJ, The</i> , 2020, 368, m579.	6.0	6
33	The “Nuts and Bolts” of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. <i>Journal of General Internal Medicine</i> , 2020, 35, 3730-3732.	2.6	1
34	Industry funding of patient and health consumer organisations: systematic review with meta-analysis. <i>BMJ, The</i> , 2020, 368, l6925.	6.0	44
35	Information and promotional strategies by pharmaceutical companies for clinicians. <i>The Cochrane Library</i> , 2020, , .	2.8	0
36	Impact and use of reviews and “overviews of reviews” to inform clinical practice guideline recommendations: protocol for a methods study. <i>BMJ Open</i> , 2020, 10, e031442.	1.9	9

#	ARTICLE	IF	CITATIONS
37	Medical, pharmacy and nursing students in the Baltic countries: interactions with the pharmaceutical and medical device industries. BMC Medical Education, 2020, 20, 105.	2.4	1
38	How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study. Australian Health Review, 2019, 43, 474.	1.1	11
39	Medicines Information and the Regulation of the Promotion of Pharmaceuticals. Science and Engineering Ethics, 2019, 25, 1167-1192.	2.9	39
40	Inadequate conflict of interest policies at most French teaching hospitals: A survey and website analysis. PLoS ONE, 2019, 14, e0224193.	2.5	8
41	Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. BMJ Evidence-Based Medicine, 2019, 24, 231-238.	3.5	27
42	Flawed evidence underpins approval of new cancer drugs. BMJ: British Medical Journal, 2019, 366, l5399.	2.3	7
43	Are Safety Warnings for Commonly-Used Sleeping Pills Reaching Those who Need them Most?. Journal of Law, Medicine and Ethics, 2019, 47, 442-444.	0.9	1
44	Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. JAMA Internal Medicine, 2019, 179, 982.	5.1	21
45	Secret safety warnings on medicines: A case study of information access requests. Pharmacoepidemiology and Drug Safety, 2019, 28, 551-555.	1.9	6
46	The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system. The Cochrane Library, 2019, , .	2.8	1
47	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117.	2.4	1
48	Missing data reporting in clinical pharmacy research. American Journal of Health-System Pharmacy, 2019, 76, 2048-2052.	1.0	7
49	Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576.	6.0	79
50	“Asset exchange” interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ, The, 2019, 367, l6694.	6.0	18
51	Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis. International Journal of Health Services, 2019, 49, 273-293.	2.5	21
52	Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study. BMJ Open, 2018, 8, e019027.	1.9	19
53	The marketing of testosterone treatments for age-related low testosterone or “Low T”. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 224-230.	2.3	9
54	The rise of ambiguous competing interest declarations. BMJ: British Medical Journal, 2018, 361, k1464.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. <i>Health Policy</i> , 2018, 122, 250-255.	3.0	5
56	Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards. <i>BMC Public Health</i> , 2018, 18, 1322.	2.9	2
57	The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. <i>Systematic Reviews</i> , 2018, 7, 242.	5.3	146
58	Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. <i>International Journal of Health Policy and Management</i> , 2018, 7, 504-509.	0.9	68
59	Mental Health Messages in Prominent Mental Health Apps. <i>Annals of Family Medicine</i> , 2018, 16, 338-342.	1.9	46
60	Industry sponsorship and research outcome: systematic review with meta-analysis. <i>Intensive Care Medicine</i> , 2018, 44, 1603-1612.	8.2	97
61	Industry sponsorship and research outcome. <i>The Cochrane Library</i> , 2017, 2017, MR000033.	2.8	772
62	Response to "cause of domperidone and risk of ventricular arrhythmia in the postpartum period: Getting to the heart of the matter": <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 865-866.	1.9	1
63	A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. <i>BMJ Open</i> , 2017, 7, e016701.	1.9	25
64	Mental health care and suicide in pregnancy and postpartum. <i>Cmaj</i> , 2017, 189, E1498-E1498.	2.0	0
65	A health app developer's guide to law and policy: a multi-sector policy analysis. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 141.	3.0	45
66	Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2549-2556.	2.4	5
67	Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. <i>PLoS ONE</i> , 2017, 12, e0168258.	2.5	28
68	The Tip of the Iceberg of Misleading Online Advertising Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters". <i>International Journal of Health Policy and Management</i> , 2016, 5, 329-331.	0.9	7
69	Postpartum domperidone use in British Columbia: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E13-E19.	2.4	25
70	The association between domperidone and ventricular arrhythmia in the postpartum period. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1210-1214.	1.9	25
71	Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. <i>Obstetrics and Gynecology</i> , 2016, 127, 553-561.	2.4	37
72	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. <i>Age and Ageing</i> , 2016, 45, 535-542.	1.6	60
74	The Inclusion of Nurses in Pharmaceutical Industryâ€“Sponsored Events. <i>JAMA Internal Medicine</i> , 2016, 176, 1718.	5.1	13
75	Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States. <i>Journal of Law, Medicine and Ethics</i> , 2016, 44, 602-615.	0.9	5
76	In Reply. <i>Obstetrics and Gynecology</i> , 2016, 128, 406-406.	2.4	0
77	Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 13.	2.4	17
78	Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. <i>Accountability in Research</i> , 2016, 23, 257-279.	2.4	25
79	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12
80	Authorsâ€™ reply to Lee and colleagues. <i>BMJ, The</i> , 2015, 351, h3737.	6.0	0
81	Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002â€“2011: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0128312.	2.5	58
82	Overdiagnosis of bone fragility in the quest to prevent hip fracture. <i>BMJ, The</i> , 2015, 350, h2088-h2088.	6.0	89
83	When drugs don't make it to market. <i>BMJ, The</i> , 2015, 350, h2852-h2852.	6.0	2
84	Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. <i>British Medical Bulletin</i> , 2015, 116, ldv042.	6.9	7
85	New oral anticoagulants. <i>Cmaj</i> , 2015, 187, 603.1-603.	2.0	0
86	Regulating prescription drugs for patient safety: Does Bill C-17 go far enough?. <i>Cmaj</i> , 2014, 186, E287-E292.	2.0	9
87	A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. <i>International Journal of Risk and Safety in Medicine</i> , 2014, 26, 213-225.	0.6	14
88	Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature. <i>Drugs and Aging</i> , 2014, 31, 55-65.	2.7	7
89	Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 242.	2.4	110
90	Pharmaceutical Sales Representatives and Patient Safety. <i>Journal of General Internal Medicine</i> , 2013, 28, 1395-1395.	2.6	2

#	ARTICLE	IF	CITATIONS
91	Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. <i>Journal of General Internal Medicine</i> , 2013, 28, 1368-1375.	2.6	79
92	A Leap of Faith in Antidepressant Treatment?. <i>JAMA Psychiatry</i> , 2013, 70, 1373.	11.0	2
93	Medication safety: opening up the black box. <i>BMJ Quality and Safety</i> , 2013, 22, 702-704.	3.7	0
94	Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. <i>PLoS ONE</i> , 2013, 8, e68633.	2.5	38
95	New UK guidance on industry-health professional collaboration. <i>BMJ</i> , The, 2012, 344, e3952-e3952.	6.0	1
96	Review overemphasises benefits and downplays serious harms. <i>BMJ</i> , The, 2012, 345, e5989-e5989.	6.0	1
97	Advertising of Prescription-Only Medicines to the Public: Does Evidence of Benefit Counterbalance Harm?. <i>Annual Review of Public Health</i> , 2012, 33, 259-277.	17.4	66
98	Disease mongering and low testosterone in men: the tale of two regulatory failures. <i>Medical Journal of Australia</i> , 2012, 196, 619-621.	1.7	16
99	Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001-2006). <i>Clinical Therapeutics</i> , 2012, 34, 239-249.e2.	2.5	81
100	Paroxetine is associated with malformation during pregnancy. <i>BMJ: British Medical Journal</i> , 2011, 343, d5060-d5060.	2.3	3
101	Is patient information on prescribed drugs just another form of advertising?. <i>BMJ: British Medical Journal</i> , 2011, 343, d4899-d4899.	2.3	1
102	Diagnosis, Pathophysiology, and Management of Mood Disorders in Pregnant and Postpartum Women. <i>Obstetrics and Gynecology</i> , 2011, 118, 708.	2.4	3
103	Regulation of formula advertising in the Philippines and promotion and protection of breastfeeding: A commentary on Sobel, Iellamo, Raya, Padilla, OlivÃ© and Nyunt-U. <i>Social Science and Medicine</i> , 2011, 73, 1449-1451.	3.8	2
104	Antidepressants and pregnancy. <i>Cmaj</i> , 2011, 183, 585-585.	2.0	0
105	The Sources and Popularity of Online Drug Information: An Analysis of Top Search Engine Results and Web Page Views. <i>Annals of Pharmacotherapy</i> , 2011, 45, 350-356.	1.9	35
106	The ethics of randomized placebo controlled trials of antidepressants with pregnant women. <i>International Journal of Risk and Safety in Medicine</i> , 2010, 22, 7-16.	0.6	14
107	Twelve Years' Experience with Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale. <i>PLoS ONE</i> , 2009, 4, e5699.	2.5	27
108	Opinion: Direct-to-consumer advertising of prescription medicines: a counter argument. <i>Future Medicinal Chemistry</i> , 2009, 1, 1555-1560.	2.3	6

#	ARTICLE	IF	CITATIONS
109	Should Canada allow direct-to-consumer advertising of prescription drugs?: no. Canadian Family Physician, 2009, 55, 131, 133, 135 passim.	0.4	6
110	Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?. Pharmacoconomics, 2008, 26, 557-566.	3.3	7
111	Should Paroxetine Be Used to Treat Depression During Pregnancy?. American Journal of Psychiatry, 2008, 165, 1487-1487.	7.2	4
112	Direct to consumer advertising of prescription drugs. BMJ: British Medical Journal, 2008, 337, a985-a985.	2.3	9
113	Does Venlafaxine Maintenance Therapy Prevent Depression Recurrences or Drug Discontinuation Reactions?. Journal of Clinical Psychiatry, 2008, 69, 865-866.	2.2	0
114	Disease Mongering in Drug Promotion: Do Governments Have a Regulatory Role?. PLoS Medicine, 2006, 3, e198.	8.4	60
115	Direct to consumer advertising. BMJ: British Medical Journal, 2005, 330, 5-6.	2.3	51
116	Medicine by media: Did a critical television documentary affect the prescribing of cyproterone-estradiol (Diane-35)?. Cmaj, 2005, 173, 1313-1315.	2.0	9
117	Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. Cmaj, 2003, 168, 1133-7.	2.0	52
118	How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Cmaj, 2003, 169, 405-12.	2.0	60
119	Direct-to-consumer prescription drug advertising in Canada: permission by default?. Cmaj, 2003, 169, 425-7.	2.0	11
120	Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No. Journal of Public Policy and Marketing, 2002, 21, 194-201.	3.4	106
121	Unbranded advertising of prescription medicines to the public by pharmaceutical companies. The Cochrane Library, 0, , .	2.8	1
122	Information and promotional strategies by pharmaceutical companies for clinicians. The Cochrane Library, 0, , .	2.8	0